FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma

Launched by SINGAPORE GENERAL HOSPITAL · Dec 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging test called O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET to help doctors tell the difference between two important conditions in patients with high-grade glioma, a type of brain cancer. Sometimes, after treatment, a patient's scans can show changes that make it hard to know if the cancer is actually getting worse (tumor progression) or if these changes are just a temporary effect of treatment (pseudoprogression). The goal is to see how accurately FET PET can identify true tumor progression and to refine the test to improve its ability to distinguish between these two conditions.

To take part in this trial, participants need to be adults aged 21 or older who have been diagnosed with malignant glioma (grades III or IV) and have had radiation therapy. They should have MRI scans showing growing areas of concern in the brain. However, individuals with low-grade gliomas, certain treatment histories, or specific genetic mutations are not eligible. If you join the trial, you can expect to have a PET scan of your brain at the study site to help collect important information about your condition, which may lead to better ways to monitor glioma in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men or Women, aged 21 years or older at time of screening
• • Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour
• • With enlarging contrast-enhancing and/or T2W/FLAIR-hyperintense lesion(s) on MRI within the previous RT field
• • Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry
• • Subject must consent to undergo all study procedures
• Exclusion Criteria:
• • Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17
• • Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments.
• • Proven cerebral metastases
• • IDH-mutated gliomas
• • Pregnancy/ breast-feeding